There is a good news for the obese or overweight patients of Switzerland that the weight loss pill rimonabant(acomplia/zimulti) has been approved for sale in the country on April 3rd 2007.Now it can be possible to make a treatment of obese patients by this with the risk of cardiovascular .
Switzerland where acomplia has been approved is not a member of the European Union which is same as EU marketing approval last june.Now the obese people can take acomplia in combination with diet and exercise with the risk of type 2 diabetes.
The obese patients having BMI greater than 30 or the overweight patients having BMI over 27 are authorized by the regulator Swissmedic to consume the weight loss pill acomplia which has at least one cardiovascular risk factor.
The weight loss pill acomplis is still held up in the key United States market . Now the FDA’s Endocrinologic and Metabolic Durgs Advisoy Committee has scheduled on June 13th ,2007 to review the acomplia.
No comments:
Post a Comment